Skip to content

Breast Study Investigating a New Light Technique to Monitor Changes in Breast Tissue Density

Optical Quantification of Breast Density Changes Due to Hormone Treatment, Pregnancy and Breast-feeding.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00188760
Enrollment
300
Registered
2005-09-16
Start date
2004-05-31
Completion date
2010-09-30
Last updated
2011-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast Transillumination Spectroscopy, Optical Transillumination Spectroscopy, Breast Cancer Risk

Brief summary

The purpose of this study is to test the ability of a technique called Transillumination Breast Spectroscopy (TIBS) to monitor an individual's breast density changes over time.

Detailed description

Breast density is an established physical risk factor for breast cancer, applicable to the entire female population in a pre-breast-screening program and, unlike other risk factors, was shown to be affected by an intervention treatment. High breast tissue density is associated with increased risk of breast cancer. Transillumination Breast Spectroscopy (TIBS) uses a white light to provide spectral information on breast tissue density and composition (e.g. water, lipid, hemoglobin and other biomolecules). The overall goal of the TIBS program is to develop a technique that can identify individuals at high risk for breast cancer who would benefit most from improved screening methods and a risk reducing intervention (e.g. diet and lifestyle changes) and can monitor the efficacy of the risk reducing intervention itself in an individual. In a previous study, we demonstrated a high correlation between breast density assessed by TIBS and density identified by x-ray mammography. The current study is testing TIBS ability to monitor changes in an individual's breast density over time

Interventions

None listed

Sponsors

Susan G. Komen Breast Cancer Foundation
CollaboratorOTHER
Dr. Julia Knight (research collaborator)
CollaboratorUNKNOWN
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Be in good health and able to provide consent * Be between 25 and 45 years of age * Be pre-menopausal * Are willing to come in to Princess Margaret Hospital (Toronto, Ontario, Canada) for up to 12 visits at intervals of about three months

Exclusion criteria

* Have had a full term pregnancy * Have had breast biopsy * Have had breast augmentation or reduction

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026